Wall Street analysts expect PerkinElmer, Inc. (NYSE:PKI) to announce sales of $644.45 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for PerkinElmer’s earnings. The lowest sales estimate is $642.86 million and the highest is $646.46 million. PerkinElmer posted sales of $643.97 million in the same quarter last year, which suggests a positive year-over-year growth rate of 0.1%. The business is scheduled to issue its next earnings results on Monday, April 29th.

On average, analysts expect that PerkinElmer will report full-year sales of $2.89 billion for the current year, with estimates ranging from $2.88 billion to $2.90 billion. For the next year, analysts anticipate that the company will post sales of $3.08 billion, with estimates ranging from $3.05 billion to $3.14 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that that provide coverage for PerkinElmer.

PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Thursday, January 31st. The medical research company reported $1.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.02. PerkinElmer had a net margin of 8.56% and a return on equity of 15.89%. The firm had revenue of $756.35 million for the quarter, compared to the consensus estimate of $746.15 million. During the same quarter in the prior year, the company posted $0.97 earnings per share.

Several analysts have recently commented on PKI shares. CIBC reiterated an “average” rating and issued a $44.50 target price on shares of PerkinElmer in a report on Thursday, January 10th. Morgan Stanley lowered their target price on shares of PerkinElmer from $100.00 to $86.00 and set an “overweight” rating for the company in a report on Thursday, January 3rd. UBS Group set a $92.00 target price on shares of PerkinElmer and gave the company a “hold” rating in a report on Saturday, February 2nd. Needham & Company LLC started coverage on shares of PerkinElmer in a report on Wednesday, January 2nd. They issued a “hold” rating and a $79.00 target price for the company. Finally, Cowen reiterated a “hold” rating and issued a $85.00 target price on shares of PerkinElmer in a report on Sunday, January 6th. Nine research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $85.06.

In other PerkinElmer news, Director Alexis P. Michas sold 2,118 shares of the company’s stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $92.96, for a total value of $196,889.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Prahlad R. Singh sold 3,289 shares of the company’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $102.39, for a total value of $336,760.71. Following the completion of the transaction, the insider now owns 28,242 shares of the company’s stock, valued at $2,891,698.38. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,475 shares of company stock worth $5,910,744. Insiders own 1.80% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Oregon Public Employees Retirement Fund boosted its holdings in shares of PerkinElmer by 0.9% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 12,045 shares of the medical research company’s stock worth $946,000 after purchasing an additional 110 shares during the last quarter. Advisors Asset Management Inc. boosted its holdings in PerkinElmer by 0.3% in the fourth quarter. Advisors Asset Management Inc. now owns 39,198 shares of the medical research company’s stock valued at $3,079,000 after acquiring an additional 132 shares in the last quarter. National Asset Management Inc. boosted its holdings in PerkinElmer by 0.8% in the fourth quarter. National Asset Management Inc. now owns 20,876 shares of the medical research company’s stock valued at $1,640,000 after acquiring an additional 160 shares in the last quarter. Contravisory Investment Management Inc. boosted its holdings in shares of PerkinElmer by 5.0% during the 4th quarter. Contravisory Investment Management Inc. now owns 5,232 shares of the medical research company’s stock valued at $411,000 after buying an additional 249 shares in the last quarter. Finally, Lindbrook Capital LLC bought a new stake in shares of PerkinElmer during the 4th quarter valued at $25,000. 96.39% of the stock is currently owned by institutional investors and hedge funds.

PKI traded down $0.25 during trading on Friday, hitting $100.85. 5,298 shares of the company’s stock were exchanged, compared to its average volume of 534,621. The company has a current ratio of 1.60, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. PerkinElmer has a fifty-two week low of $70.83 and a fifty-two week high of $103.00. The company has a market cap of $11.21 billion, a price-to-earnings ratio of 27.88, a PEG ratio of 2.21 and a beta of 1.25.

The company also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Stockholders of record on Friday, April 19th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend is Wednesday, April 17th. PerkinElmer’s payout ratio is 7.76%.

About PerkinElmer

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.

Featured Article: How to trade on quiet period expirations

Get a free copy of the Zacks research report on PerkinElmer (PKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.